144 related articles for article (PubMed ID: 36084297)
1. A Case Report of Conjunctival Extranodal Marginal Zone Lymphoma Treated with Intralesional Rituximab Injection Therapy.
Yazicioglu T; Oklar M; Kocabas S; Karadag E; Elibol V; Tezcan ME
Ocul Immunol Inflamm; 2022 Aug; 30(6):1329-1333. PubMed ID: 36084297
[TBL] [Abstract][Full Text] [Related]
2. A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy.
Celiker H; Toker E; Kaygusuz Atagunduz I
Int Ophthalmol; 2019 Mar; 39(3):687-691. PubMed ID: 29411260
[TBL] [Abstract][Full Text] [Related]
3. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
[No Abstract] [Full Text] [Related]
4. Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum.
Ferreri AJM; Sassone M; Miserocchi E; Govi S; Cecchetti C; Corti ME; Mappa S; Arcaini L; Zaja F; Todeschini G; Mannina D; Calimeri T; Perrone S; Ponzoni M; Modorati G
Blood Adv; 2020 Mar; 4(6):1013-1019. PubMed ID: 32182364
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.
Nückel H; Meller D; Steuhl KP; Dührsen U
Eur J Haematol; 2004 Oct; 73(4):258-62. PubMed ID: 15347312
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
[TBL] [Abstract][Full Text] [Related]
7. [The preliminary observation of intralesional rituximab administration in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma].
Yang JP; Pang X; Zhang K; Wang LL; Zhu Y
Zhonghua Yan Ke Za Zhi; 2020 Nov; 56(11):839-845. PubMed ID: 33152842
[No Abstract] [Full Text] [Related]
8. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
9. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
[TBL] [Abstract][Full Text] [Related]
10. Conjunctival Lymphoma.
McGrath LA; Ryan DA; Warrier SK; Coupland SE; Glasson WJ
Eye (Lond); 2023 Apr; 37(5):837-848. PubMed ID: 35882984
[TBL] [Abstract][Full Text] [Related]
11. Regression of pulmonary MALT lymphoma after treatment with rituximab.
Chong EA; Svoboda J; Cherian S; Andreadis C; Downs LH; Zhuang H; Alavi A; Tsai DE; Schuster SJ
Leuk Lymphoma; 2005 Sep; 46(9):1383-6. PubMed ID: 16109620
[TBL] [Abstract][Full Text] [Related]
12. Treatment of localized oral MALT lymphoma by rituximab: a case report.
Yamagata K; Onizawa K; Kojima H; Yoshida H
Oral Maxillofac Surg; 2008 Dec; 12(4):227-30. PubMed ID: 18830723
[TBL] [Abstract][Full Text] [Related]
13. Intralesional rituximab in primary conjunctival follicular lymphoma relapsed.
Rodríguez Villa S; Ruiz Rodríguez MJ; Vargas Pabón M
Arch Soc Esp Oftalmol; 2017 Jul; 92(7):326-329. PubMed ID: 27986437
[TBL] [Abstract][Full Text] [Related]
14. Favourable response to rituximab by an ocular adnexal primary lymphoma.
Luque Valentin-Fernandez ML; Alvarez Rodríguez F; Rodríguez Jiménez I
Arch Soc Esp Oftalmol; 2016 Nov; 91(11):539-542. PubMed ID: 27125186
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymph tissue: A case report and literature review.
Wu Y; Zhao L; Chai Y
Niger J Clin Pract; 2018 Mar; 21(3):392-394. PubMed ID: 29519992
[TBL] [Abstract][Full Text] [Related]
16. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
Kyrtsonis MC; Siakantaris MP; Kalpadakis C; Dimopoulou MN; Vassilakopoulos TP; Kontopidou FN; Antoniou C; Korkolopoulou P; Panayiotidis P; Pangalis GA
Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
[TBL] [Abstract][Full Text] [Related]
17. Paediatric and adolescent elevated conjunctival lesions in the plical area: lymphoma or reactive lymphoid hyperplasia?
Beykin G; Pe'er J; Amir G; Frenkel S
Br J Ophthalmol; 2014 May; 98(5):645-50. PubMed ID: 24162623
[TBL] [Abstract][Full Text] [Related]
18. Intralesional interferon-α for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results.
Blasi MA; Tiberti AC; Valente P; Laguardia M; Sammarco MG; Balestrazzi A; Larocca LM; Balestrazzi E
Ophthalmology; 2012 Mar; 119(3):494-500. PubMed ID: 22226154
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
20. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
